RXi Pharmaceuticals — Update 18 April 2016

RXi Pharmaceuticals — Update 18 April 2016

RXi Pharmaceuticals

Analyst avatar placeholder

Written by

RXi Pharmaceuticals

Spotlight on cosmetic product development

Products update

Pharma and biotech

18 April 2016

Price

US$2.6

Market cap

US$17m

Net cash ($m) at end December 2015

10.67

Shares in issue

6.53m

Free float

96%

Code

RXII

Primary exchange

NASDAQ

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

(9.7)

(7.2)

(62.8)

Rel (local)

(12.5)

(16.1)

(62.4)

52-week high/low

US$7.3

US$2.6

Business description

RXi is a clinical-stage RNAi company developing therapeutics in dermatology and ophthalmology. Lead projects for RXI-109 in dermal indications (Phase II) and in ocular for wet AMD (Phase I/II) stem from its proprietary self-delivering (sd-rxRNA) platform. Licensed-in immunomodulator Samcyprone (Phase II) is initially being developed for warts, alopecia areata and melanoma.

Next events

RXI-109 Phase I/II early data wet AMD

H216

RXI-109 Phase IIa early results in dermal scarring

H216

Cosmeceutical entry consumer testing

H216

Samcyprone Phase II early read outs

H216

Analysts

Katherine Genis

+1 646 653 7026

Maxim Jacobs

+1 646 653 7027

RXi Pharmaceuticals is a research client of Edison Investment Research Limited

RXi Pharmaceuticals (RXi) continues to make solid progress with its development pipeline. We anticipate one of two promising cosmeceutical candidates to enter human testing this year, moving forward on an expedited pathway for potential launch in 2019. We also expect data in H216 in all lead projects including RXI-109 in dermal scarring and in retinal scarring in wet AMD, and Samcyprone in cutaneous warts.

Year end

Revenue ($000)

PBT*
($000)

EPS*
($)

DPS
($)

P/E
(x)

Yield
(%)

12/14

71

(6,954)

(4.25)

0.0

N/A

N/A

12/15

34

(8,510)

(1.70)

0.0

N/A

N/A

12/16e

0

(11,166)

(1.74)

0.0

N/A

N/A

12/17e

0

(12,942)

(2.01)

0.0

N/A

N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Cosmeceuticals move forward in skin appearance

In the latter part of 2015, RXi selected two treatment candidates to move forward on an expedited cosmeceuticals development pathway, RXI-231 (targeting tyrosinase to improve skin appearance) and RXI-185 (targeting collagenase for skin elasticity and anti-ageing). A successful cosmeceuticals launch could fetch sales of up to $150m and we expect at least one candidate to move into consumer testing by year end, for a targeted launch in 2019. RXi management has considerable expertise in cosmetic product development and we anticipate the completion of a series of marketing deals with large consumer product companies in coming years to bring in funds that can provide funding of RXi’s therapeutic pipeline.

Therapeutics portfolio on track for data in 2016

RXi is steadily advancing all three of its clinical programs. It will announce six-month data from its Phase II trial in hypertrophic scarring toward the latter part of the year, having identified optimal dosing and treatment duration. Full study results are expected mid-2017. We also look forward to full enrolment and early read outs this year from a Phase II study with Samcyprone in cutaneous warts. RXi recently initiated a Phase I/II trial in retinal scarring associated with wet-age macular generation, a potentially multi-billion dollar market. RXi has indicated that preliminary safety read-outs for the trial are expected in the second half of 2016, reporting that two patients have been dosed to date without safety issues.

Valuation: Moves up to $107.2m ($16.5 per share)

Our valuation for RXi moves to $107.2m ($16.50 per share) from $91m ($14.0 per share) based on an NPV of lead projects and reflecting the recent 1-10 reverse share split. The increase relates to first-time inclusion of a risk adjusted value for one cosmeceutical in our model. We also increase chances of success for Samcyprone (30% from 20%) and RXI-109 in AMD from (10% from 5%) on the start of their Phase I and Phase II trials. Estimated cash holdings of $8m (March 2016) should provide cash into late 2016, pointing to an estimated funding need of ~$20m in the next couple of years. RXi also has a $10.7m outstanding equity line available.

Two compounds move forward in cosmetic use

In October 2015, RXi announced the selection of two compounds for initial cosmetic product development, RXI-231 and RXI-185, which are both based on the company’s self-delivering RNAi (sd-rxRNA) platform and target the tyrosinase and collagenase enzymes respectively. The company aims to move one of these candidates forward in consumer testing by the end of 2016. In vitro, the compounds have shown a high potency and dose-dependent lowering of the messenger RNA expression of the enzymes, thereby holding the potential to impact alterations in skin tone, texture and pigmentation. Tests to date in monolayer cell cultures and culture human skin equivalents confirm their effect on messenger RNA. RXi plans to move these compounds, which both hold IP protection through at least 2029, on an expedited cosmeceutical development path with the aim to launch at least one on to the market through multiple partnerships, in and around 2019. Potential cash inflow received from the out licensing of the treatments would be earmarked for the funding of later-stage trials of existing clinical compounds in development.

RXi is developing RXI-231 – targeting tyrosinase – to improve skin appearance. Tyrosinase is the key enzyme involved in melanin synthesis, providing color to hair and skin. As shown in Exhibit 1, RXI-231 has shown a visible reduction of pigmentation in melanocytes in human epidermis tissue cultures, also displaying 100-fold potency over well-known skin lightening agent, kojic acid (marketed by Unilever, which registers annual global sales of more than $1bn per year). Collagenases are enzymes that break the peptide bonds in collagen. RXI-185, targeting collagenase matrix metalloproteinase-1 (MMP-1), has been selected for its potential in skin improvement/anti-ageing. Collagen reduces naturally in the ageing process or due to sun exposure eventually leading to wrinkles. Reduced collagen also causes acne scarring. RXI-185 therefore holds the potential to improve the appearance, texture and elasticity of the skin. RXi is focused on working on a topical delivery for both RXI-231 and RXI-185 and evaluating potential alternative delivery to enhance penetration past the skin surface to reach the lower layers of the epidermis and improve absorption in the skin for further impact.

Exhibit 1: Reduction of pigmentation in vitrosd-rxRNA targeting TYR

Source: RXi company presentation February 2016

The cosmeceutical development path to market is potentially much shorter than that for therapeutics. Cosmeceuticals are not intended to treat or prevent disease and the regulatory requirements are less rigorous with in vitro lab work only required – no animal data – before human testing. The human testing process normally entails specific evaluation methods such as Chroma Meters to look at the degree of pigmentation or elasticity measurements of the skin to monitor changes over time. RXI-213 and RXI-185 are in functional safety testing and will move to consumer testing thereafter. Following product optimization, RXi anticipates the potential commercialization toward the end of the decade.

RXi estimates the total worldwide market for higher-end skin improvements, which includes retinols and other pigmentation products, at ~$2-3bn and growing 10% a year. Given the high potency of RXi’s compounds, distributors would initially target the premium cosmetic segment for anti-wrinkle, skin laxity, uneven skin tone and pigmentation. Consistent with other premium branded skin products, management indicates initial pricing of its treatments to the consumer would average $400-500 for a one-year supply. Thereafter, further branding would likely follow into lower priced market segments following industry precedent, eg Johnson & Johnson (J&J) RoC retinol originally sold in department stores, before cascading down market via the Neutrogena brand, and then arriving at supermarkets as Aveeno. For forecasting purposes we consider J&J’s anti-ageing cream, retinol, an apt comparator; under its various brands it commands annual revenue of ~$150m. Assuming the launch of just one of RXi’s lead compounds in 2019, we conservatively forecast peak sales of RXI-231 and RXI-185 around 25% of the retinol level, with a gradual build out of brands until patent expiry in 2029. RXi is exploring options for internal or collaborative development paths having received multiple requests from potential partners. Potential partners include large consumer goods companies such as Unilever, P&G, J&J and Shiseido and commercialization would likely span geographic regions. As guided by management we anticipate RXi will receive one-time milestones of ~$2m from each of several distributors based on prior similar industry collaborations. RXi management believes that royalties on sales to distributors of 3-5% are realistic based on industry norms.

Management also reports multiple potential follow-on compounds targeting tyrosinase and collagenase as possible candidates for development on a therapeutics path, which may be used through prescription in multiple areas such as ageing disorders, arthritis and blistering skin complaints.

RXi looks well positioned to move RXI-231 and RXI-185 forward on a cosmeceuticals path given considerable prior managerial experience in the commercialization of cosmetic products. CEO Geert Cauwenbergh has the background and expertise to help bring these programs forward, having worked a number of years for J&J in charge of developing the skin care franchise for the beauty and cosmetic consumer.

Pipeline progress with the initiation of two key trials

RXi continues to progress its therapeutics pipeline, which is principally developed through its own self delivering RNAi platform. Two key trials were initiated in recent months: a Phase I/II with RXI-109 in ophthalmology and Phase II for the in-licensed Samcyprone in cutaneous warts. Additionally, RXi is moving forward with its Phase II trial for RXI-109 in hypertrophic scarring having identified best dosing (5 milligrams per centimeter of incision length) and now exploring six-month treatment regiments (previously three months) recognizing that extending the dose will support a more sustained response during the primary period of scar formation. Six-month data are anticipated in mid-2016 and fully study results expected in mid-2017.

Exhibit 2: RXi therapeutic and cosmetic pipeline

Treatment

Indication

Status

RXI-109

Hypertrophic scars

Phase II updates end 2016, full results mid 2017

RXI-109

Retinal scarring (wet AMD)

Phase I/II initiated Q415 for first read-out H216

RXI-109

Corneal scarring

Pre-clinical

Samcyprone

Cutaneous warts

Phase II full enrolment and early read-out 2016

Samcyprone

Alopecia areata, cutaneous metastases of melanoma

Phase II investigator sponsored trials

RXI-231 and RXI-185

Cosmeceutical development path

Human testing of one compound by end 2016

Source: Edison Investment Research

Phase I/II initiated in retinal scarring

In November 2015 RXi announced the start of a Phase I/II trial evaluating the safety and clinical activity of RXI-109 for retinal scarring, a common and damaging effect of multiple retinal diseases including wet age-related macular degeneration. The initial study, RXI-109-1501, is a multi-centered dose escalation trial in wet age-related macular degeneration (wet AMD). A small number of patients are receiving four doses of RXI-109 at one month intervals administered by intravitreal injection in one eye with evaluation for safety and tolerability utilizing assessment monitoring ocular health and visual acuity. First dosing will be followed by a four-month observation period to assess ocular health. Two patients have been dosed to date without safety issues, with one receiving all four doses and one three doses. A second cohort is planned to start in the coming weeks. Criteria on enrolment is stringent including a requirement that patients have some level of retinal scarring enabling an evaluation of any effect by RXI-109 on the rate of growth of the scar. RXi indicated at the time of its 2015 full-year results that preliminary safety read-outs for the trial are expected in the second half of 2016.

AMD is a leading cause of vision loss in people aged over 65 and represents a significant market opportunity. Anti-VEGF treatment (Lucentis, EYLEA at ~$2bn in 2015 sales) and photodynamic or laser surgery can stabilize or improve vision, however, scar formation after treatment has been identified as one of the main causes of the loss of visual acuity. The RXI-109 is in testing as a supplement to Anti-VEGF treatment. We forecast peak sales potential for RXI-109 in AMD of $1.3bn in 2030 assuming 25% market penetration. Our forecast for RXI-109 in ocular indications is limited to revenue for treatment in wet AMD only. However, we point to its much larger potential when including other possible ocular diseases where sub retinal fibrosis is a component including proliferative vitreoretinopathy (PVR) and proliferative diabetic retinopathy (PDR).

Samcyprone Phase II to be fully enrolled by end 2016

In late December RXi announced the formal start of a Phase II trial evaluating the safety and efficacy of topical gel, Samcyprone, on cutaneous warts – benign epidermal tumors caused by the human papillomavirus (HPV). The multi-center and multi-dose trial, named RXI-SCP-1502, will evaluate 40 subjects with at least one cutaneous, plantar or periungal wart for a minimum of four weeks. Following sensitization treatment (on the inner arm), subjects will receive 10 weekly treatments and evaluated on an Investigator’s Global Assessment Score (IGAS) and wart measurement with the goal of complete eradication of the wart and a return of the skin to normal appearance. RXi management expects the trial to be fully enrolled by end 2016 with early read-outs anticipated in H216, enabling a safety database to support investigator sponsored trials in added indications.

RXI licensed in Samcyprone, a proprietary ointment formulation of the topical immunomodulator diphenylcyclopropenone1, early in 2015. The gel works through the initiation of a T-cell response by altering the expression of multiple genes and miRNAs in the immune response. The clinical program focuses on viral warts and augments ongoing trials by independent investigators in alopecia areata (baldness) and in cutaneous metastases of malignant melanoma, an indication with orphan drug status. Other potential indications for Samcyprone include actinic keratosis, basal-cell carcinoma, squamous-cell carcinoma and cutaneous metastasis of non-melanoma cancers. Our model includes peak sales for Samcyprone of $177m in 2027 in hard-to-treat warts only at 50% penetration.

  Diphenylcyclopropenone (DPCP) is not FDA approved and must be formulated in acetone by a pharmacist. It has been in use in dermatology centers for more than 30 years mainly to stimulate hair growth in patients with alopecia areata.

Valuation

Our valuation, at $107.2m or $16.5 per share, moves up from $91m or $14.0 per share ($11.7 per diluted share) since our last report of 3 November and is based on an NPV of lead pipeline projects, applying Edison’s standard 12.5% discount. We now include a value for one cosmeceutical compound (RXI-231 or RXI-185) in our formal valuation assuming a risk adjustment of 20% given the need for functional safety testing ahead of trials in humans, but also the potential faster and less complex approval process for these compounds. Our risk adjustments move up for Samcyprone from 20% from 30% and for RXI-109 in AMD from 5% to 10% on the start of their respective Phase I and Phase II trials. Rolling forward our DCF by one quarter causes marginal changes to our valuation.

Exhibit 3: Valuation

Product

Launch

Peak sales ($m)

Risk adjustment

Royalty rate

rNPV
($m)

rNPV/share
($)

RX-109 in scarring

2021

1,453

20%

17.5%

75.8

11.67

RX-109 in AMD

2022

1,077

10%

15%

10.4

1.60

Samcyprone

2020

177

30%

17.5%

10.2

1.57

Cosmeceutical

2019

250

20%

4%

2.9

0.45

Implied enterprise value

99.3

15.30

Net cash est. (31 March 2016)

7.8

1.20

Overall valuation

107.2

16.50

Source: Edison Investment Research

Financials

Our forecasts remain largely unchanged since our last review of the company. RXi reported full-year and fourth-quarter results on 30 March, with a net loss of $2.6m in Q4 fully in line with our expectations. The company maintained its lean operating structure in 2015, reporting R&D expenses of $1.7m in Q415 (vs $1.6m in Q415) and SG&A of $0.9m in Q415 (vs $0.8m in Q414). We estimate that RXi has a cash runway extending into the latter part of 2016 based on cash holdings of approximately $10.6m at December 2015. Additionally, RXi has $10.7m available from an outstanding equity line. The cash runway would also be extended if share rights issued in conjunction with its equity fundraising in 2015 are exercised which, at an option price of $0.46, could yield funds of up to $5.7m. Our forecasts include $10m in illustrative long-term debt in our model in each of 2016 and 2017, ie a $20m near-term funding requirement, mainly to cover expected R&D costs. However, management has also pointed out potential business and corporate development options to strengthen the company’s financial position with hope of additional information in the coming months.

RXi said in March that the company issued a proxy to request permission from shareholders to initiate a reverse split to establish the minimum Nasdaq listing requirement of a share price of at least $1 per share. On 15 April the company announced a reverse stock split of its shares of common stock at a ratio of 1-10 effective 18 April. The share split was carried out in order to ensure a per share trading price of at least $1.00 (for ten consecutive days) in accordance with Nasdaq requirements. Management cited the importance of the Nasdaq listing in its ability to further business and corporate development initiatives.

Exhibit 4: Financial summary

$'000s

2013

2014

2015

2016e

2017e

Year end 31 December

US GAAP

US GAAP

US GAAP

US GAAP

US GAAP

PROFIT & LOSS

Revenue

 

 

399

71

34

0

0

Cost of Sales

0

0

0

0

0

Gross Profit

399

71

34

0

0

Research and development

(5,401)

(5,680)

(6,925)

(9,000)

(10,000)

General & administrative

(3,697)

(3,217)

(3,346)

(3,614)

(3,975)

EBITDA

 

 

(6,819)

(7,067)

(8,550)

(11,096)

(12,430)

Operating Profit (before GW and except.)

 

 

(6,720)

(6,980)

(8,474)

(11,048)

(12,378)

Intangible Amortisation

0

0

0

0

0

Exceptionals/Other

(12,250)

0

(228)

0

0

Share-based payments

(1,979)

(1,846)

(1,535)

(1,566)

(1,597)

Operating Profit

(18,970)

(6,980)

(8,702)

(11,048)

(12,378)

Net Interest

24

17

14

(299)

(750)

Other (includes change in fair value of warrants)

0

9

0

0

0

Profit Before Tax (norm)

 

 

(6,696)

(6,954)

(8,460)

(11,347)

(13,128)

Profit Before Tax (FRS 3)

 

 

(20,925)

(8,800)

(10,223)

(12,913)

(14,725)

Tax

0

0

0

0

0

Deferred tax

0

0

0

0

0

Profit After Tax (norm)

(6,696)

(6,954)

(8,460)

(11,347)

(13,128)

Profit After Tax (FRS 3)

(20,925)

(8,800)

(10,223)

(12,913)

(14,725)

Average Number of Shares Outstanding (m)

10.3

16.4

49.7

6.5

6.5

EPS - normalised fully diluted ($)

 

 

(6.52)

(4.25)

(1.70)

(1.74)

(2.01)

EPS - FRS 3 ($)

 

 

(28.78)

(7.90)

(2.10)

(1.98)

(2.26)

Dividend per share ($)

0.0

0.0

0.0

0.0

0.0

BALANCE SHEET

Fixed Assets

 

 

195

201

181

191

199

Intangible Assets

0

0

0

0

0

Tangible Assets

177

183

163

173

181

Other

18

18

18

18

18

Current Assets

 

 

14,743

8,988

10,978

9,628

6,493

Stocks

0

0

0

0

0

Debtors

0

0

0

0

0

Cash

14,440

8,546

10,667

9,318

6,183

Other

303

442

311

310

310

Current Liabilities

 

 

(2,076)

(1,334)

(2,269)

(2,269)

(2,269)

Creditors

(2,076)

(1,334)

(2,269)

(2,269)

(2,269)

Short term borrowings

0

0

0

0

0

Long Term Liabilities

 

 

0

0

0

(10,000)

(20,000)

Long term borrowings

0

0

0

(10,000)

(20,000)

Other long term liabilities

0

0

0

0

0

Net Assets

 

 

12,862

7,855

8,890

(2,449)

(15,577)

CASH FLOW

Operating Cash Flow

 

 

(6,311)

(7,758)

(8,025)

(11,299)

(13,376)

Net Interest

0

0

0

0

0

Tax

0

0

0

0

0

Capex

(78)

(95)

(57)

(58)

(60)

Acquisitions/disposals

0

12

0

0

0

Financing

15,684

1,947

9,495

0

0

Dividends

0

0

0

0

0

Other

(35)

0

708

0

0

Net Cash Flow

9,260

(5,894)

2,121

(11,358)

(13,436)

Opening net debt/(cash)

 

 

(5,180)

(14,440)

(8,546)

(10,667)

682

HP finance leases initiated

0

0

0

0

0

Exchange rate movements

0

0

0

0

0

Other

0

0

0

(1)

0

Closing net debt/(cash)

 

 

(14,440)

(8,546)

(10,667)

692

14,117

Source: RXi financial accounts, Edison Investment Research. Note: EPS updated for the 1-10 reverse share split

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by RXi Pharmaceuticals and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2016. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Euromax Resources — Update 18 April 2016

Euromax Resources

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free